Geographic atrophy: pathophysiology and current therapeutic strategies

Area of Science:

• Ophthalmology
• Retinal Diseases
• Age-Related Macular Degeneration (AMD)

Background:

• Geographic atrophy (GA) is an advanced stage of AMD characterized by progressive vision loss due to photoreceptor and retinal pigment epithelium (RPE) cell death.
• Risk factors include advanced age, family history, smoking, and genetic variations.
• Diagnosis relies on comprehensive eye exams and imaging like OCT and fundus photography.

Purpose of the Study:

• To review the pathophysiology of geographic atrophy (GA).
• To discuss currently approved treatments for GA, including their limitations.
• To explore potential future therapeutic strategies for GA.

Main Methods:

• Literature review of pathophysiology, diagnosis, and treatment of geographic atrophy (GA).
• Analysis of recent FDA-approved GA therapies (Syfovre and Izervay).
• Discussion of ongoing clinical trials and unmet needs in GA treatment.

Main Results:

• New FDA-approved treatments like Syfovre and Izervay demonstrate potential in slowing GA progression.
• Current therapies offer benefits but do not provide a cure and have limitations in efficacy and safety.
• Significant need exists for novel therapeutics with improved efficacy, safety, and patient compliance.

Conclusions:

• Geographic atrophy (GA) represents a significant challenge in age-related macular degeneration (AMD) management.
• While recent therapeutic advancements offer hope, they underscore the critical need for more effective treatments.
• Future research should focus on developing therapies with enhanced efficacy, better safety profiles, and improved patient adherence.